Making waves

Article

I would like to give a warm welcome to all of our readers and, particularly to those of you who have recently joined the many ophthalmologists across Europe who read our publication. I have been delighted by the response we have had to Ophthalmology Times Europe so far and I would like to thank you all for your very kind words of support and encouragement. We have tried to make Ophthalmology Times Europe a little different to other publications out there, not only in the world of ophthalmology, but across industries. By providing broad coverage of the industry and presenting arguments and ideas in an easily digestible format, it has been our mission to supply you with something that you enjoy reading.

So if you think we are missing something or if you would like to make your voice heard, please do get in touch. I am always happy to hear from you.

This month's feature, Wavefront technologies: what's best for your patient? embarks on a mission to help you find the wavefront treatment that will benefit your patient most. By profiling some of the technologies currently on the market, we have tried to give you a taste of what's out there and what impact, changing your approach to laser surgery, could have on your practice. Many studies have been published proving the benefits of wavefront treatment over conventional excimer laser surgery. However, the current argument is, of the wavefront technologies available, which one's best? There will always be issues relating to cost effectiveness and speed of treatment but take a look at the facts and make your judgement.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.